Our News

Published Scientific Articles

p27 as a target for cancer therapeutics

Differential modification of p27Kip1 controls its cyclin D-cdk4 inhibitory activity

Switching cyclin D-Cdk4 kinase activity on and off

p27Kip1 inhibits cyclin D-cyclin-dependent kinase 4 by two independent modes

Concarlo in the News

Concarlo Therapeutics Presents Novel Therapeutic Approach for ER+ Metastatic Breast Cancer Targeting the CDK Pathway

Many startups are built off research, so why don’t more scientists become founders?

CDK Inhibitors: Why Women – and Men – Should Know About This ‘New Era’ Of Cancer Treatment

Webinars & Talks

Case Study: Developing liposomal formulation of a novel 91-mer synthetic peptide for treatment of ER+ CDK4i resistant Breast Cancer

The academic to founder pipeline with Dr. Stacy Blain from Concarlo Therapeutics

Targeting p27Kip1 to Treat Drug-Resistance Cancer


“The reward for work well done is the opportunity to do more”

—Jonas Salk

RESI’s Innovator’s Pitch Challenge Winner

Princeton University Women’s Showcase

The 50 Most admired companies: CIO Bio

Top 100 entreprenuers: Alumni List

Top Biotech Startup 2022
Awarded by: Life Sciences Review